Biofrontera
Inc. (Nasdaq: BFRI),
a biopharmaceutical company specializing in the commercialization
of dermatological products, announced today that PM360, a
publication for marketing decision makers in the pharmaceutical,
biotech, diagnostics and medical device industries, has named
Leslie Hopkins, Associate Director of Marketing, as a Trailblazer
Brand Champion in the Dermatology category. The Ameluz® marketing
campaign, created by Biofrontera Inc. along with Elevate
Healthcare, also received nominations for PM360’s
“Relaunch/Revitalization of the Year” and “Professional
Website/Online Initiative of the Year” awards.
“It’s heartening to receive industry recognition
of our exceptional marketing work. In a sector that historically
has been dominated by entrenched behavior and complacent market
leaders, Leslie led the team in the relaunch of the Ameluz
campaign, increasing awareness of photodynamic therapy (PDT) as a
leading treatment for actinic keratosis (AK) especially among
patients with more than 15 AK lesions. She motivated the team to
change their thinking of AK treatment and their perception of PDT,
and pushed for stronger creative for the campaign to disrupt the
market and reinvigorate the brand. Her strategic approach,
attention to detail and dedication to her team and our brand
resulted in a highly successful relaunch,” stated Erica Monaco,
Chief Executive Officer of Biofrontera Inc.
Since 2009, the PM360 Trailblazer Awards have
recognized outstanding achievement and innovation in healthcare
marketing. Each year, nominations are judged by the PM360 Editorial
Advisory Board, a distinguished cross-section of industry experts.
Brand Champion winners are members of a brand marketing team
selected for their ability to stand out in the complex,
ever-changing healthcare environment. In particular, judges
selected winning entrants for innovation, leadership, ability to
communicate, and analytical and organizational skills.
“Being named a Trailblazer Brand Champion means
so much more than leading your brand to success,” says Anna
Stashower, CEO and Publisher of PM360. “Above all else, these
professional marketers are champions for improving patient care.
Everything they do, every healthcare stakeholder they engage with,
every strategy they enact and every channel they explore are all in
pursuit of the goal of helping patients get the treatments they
need to improve their quality of life.”
The winners will be honored during a gala
celebration at Gotham Hall in New York City on September 22
beginning at 6 p.m. Tickets can be purchased by visiting
https://cvent.me/7P0ZZL. Profiles of all of the winners will be
included in PM360’s October 2022 issue.
This year Brand Champions were selected in 22
categories: Autoimmune, Cardiology, Central Nervous System,
Dermatology, Diabetes/Metabolic Disorders, Diversity/Multicultural,
Gastrointestinal, Global Marketing, HCP Engagement,
Hematology/Oncology, Infectious Disease/Vaccine Development,
Innovation/Digital Strategy, Managed Markets/Payer Strategies,
Medical Device/Diagnostics, Men’s Health, Nephrology/Urology,
Ophthalmology/Optometry, Orthopedics/Musculoskeletal Disorders,
Patient Engagement, Rare Diseases, Respiratory and Women’s
Health.
For more information about the awards or
tickets, contact Kayla Walsh at 646-300-8114 or
kayla.walsh@pm360online.com.
About
PM360
PM360 is the premier, must-read magazine for
marketing decision makers in the pharmaceutical, biotech,
diagnostics and medical device industries. Published monthly, PM360
is the only journal that focuses on delivering the full spectrum of
practical information necessary for product managers and
pharmaceutical marketing professionals to succeed in the complex
and highly regulated healthcare environment.
The journal’s targeted and insightful editorial
focuses on issues that directly impact critical decision making,
including planning and implementation of cutting-edge strategies,
trends, the latest technological advances, branding/marketing,
advertising/promotion, patient/professional education, sales,
market research, PR and leadership. Additionally, the “360” in the
title signifies the span of this critical, how-to info with
personal and career insights for an enjoyable and thought-provoking
read.
By providing the full circle of enriching
content, PM360 is truly an indispensable tool for busy and
productive marketing professionals to stay at the top of their
game.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based
biopharmaceutical company commercializing a portfolio of
pharmaceutical products for the treatment of dermatological
conditions with a focus on photodynamic therapy (PDT) and topical
antibiotics. The Company’s licensed products are used for the
treatment of actinic keratoses, which are pre-cancerous skin
lesions, as well as impetigo, a bacterial skin infection. For more
information, visit www.biofrontera-us.com.
Forward-Looking Statements
Certain statements in this press release may
constitute "forward-looking statements" within the meaning of the
United States Private Securities Litigation Reform Act of 1995, as
amended to date. These statements include, but are not limited to,
statements relating to the Company’s business and marketing
strategy, future operations and business, potential to expand the
label of Ameluz®, market presence and position of Ameluz® and
ongoing clinical trials conducted by our licensing partners and the
future impact of such trials on the market for Ameluz®. We have
based these forward-looking statements on our current expectations
and projections about future events, nevertheless, actual results
or events could differ materially from the plans, intentions and
expectations disclosed in, or implied by, the forward-looking
statements we make. These risks and uncertainties, many of which
are beyond our control, including, but not limited to, the impact
of extraordinary external events, such as the current COVID-19
pandemic; any changes in the Company’s relationship with its
licensors; the ability of the Company’s licensors to fulfill their
obligations to the Company in a timely manner; the Company’s
ability to achieve and sustain profitability; whether the current
global disruptions in supply chains will impact the Company’s
ability to obtain and distribute its licensed products; changes in
the practices of healthcare providers, including any changes to the
coverage, reimbursement and pricing for procedures using the
Company’s licensed products; the uncertainties inherent in the
initiation and conduct of clinical trials; availability and timing
of data from clinical trials; whether results of earlier clinical
trials or trials of Ameluz® in combination with BF-RhodoLED® in
different disease indications or product applications will be
indicative of the results of ongoing or future trials;
uncertainties associated with regulatory review of clinical trials
and applications for marketing approvals; whether the market
opportunity for Ameluz® in combination with BF-RhodoLED® is
consistent with the Company’s expectations; the Company’s ability
to complete the transition to a public company; the Company’s
ability to retain and hire key personnel; the sufficiency of cash
resources and need for additional financing and other factors that
may be disclosed in the Company’s filings with the SEC, which can
be obtained on the SEC website at www.sec.gov. Readers are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management's current estimates, projections,
expectations and beliefs. The Company does not plan to update any
such forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
Contacts
Biofrontera Inc.Anke zur
Mühlen+1 781 486 1539us-ir@biofrontera.com
LHA Investor RelationsTirth T.
Patel+1 212 201 6614tpatel@lhai.com
# # #
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Oct 2023 to Oct 2024